<DOC>
	<DOCNO>NCT00207428</DOCNO>
	<brief_summary>The purpose study evaluation efficacy antiepileptic drug carbamazepine treatment mild-to-severe bronchial asthma .</brief_summary>
	<brief_title>Antiepileptic Drug Carbamazepine Treatment Bronchial Asthma</brief_title>
	<detailed_description>Effective therapy asthma still remain quite serious problem . According current opinion lead specialist , asthma inflammatory disorder . But asthma also paroxysmal disorder : many specialist underline paroxysmal clinical picture asthma . According author , neurogenic inflammation may play important role asthma mechanism . But migraine trigeminal neuralgia also neurogenic inflammatory paroxysmal disease , antiepileptic drug , like carbamazepine valproates , effective therapy diseases - 80 % case . If bronchial asthma also paroxysmal inflammatory disease , suppose possibility antiepileptic drug also may show high efficacy asthma therapy . Taken consideration hypothesis , perform double-blind , placebo-controlled 3-month trial evaluation carbamazepine efficacy treatment patient mild-to-severe bronchial asthma . Comparison : Patients receive investigational drug addition usual routine antiasthmatic treatment , compare patient receive placebo addition usual routine antiasthmatic treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Out patient Bronchial asthma know least 1 year Absence longterm remission asthma ( last 1 month ) Poorly control asthma , due various reason Nonsmokers Presence concomitant acute chronic severe diseases Abnormal baseline haematology , blood chemistry urinalysis Allergy adverse reaction investigational drug Age young 16 year old Longterm history smoking Pregnancy lactating</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1999</verification_date>
	<keyword>Bronchial asthma</keyword>
	<keyword>Carbamazepine</keyword>
	<keyword>Efficacy</keyword>
</DOC>